Related Experiment Video
Updated: Jan 17, 2026

08:43
Application of Granger Causality Analysis of the Directed Functional Connection in Alzheimer's Disease and Mild Cognitive Impairment
Published on: August 7, 2017
8.4K
ci-fGBD: Cluster-Integrated Fast Generalized Bruhat Decomposition for Multimodal Data Clustering in Alzheimer's
Medrxiv : the Preprint Server for Health Sciences
|September 15, 2025
Summary
A new matrix factorization and clustering framework, ci-fGBD (Cluster-Integrated Fast Generalized Bruhat Decomposition), effectively stratifies patients with neurodegenerative diseases. It integrates diverse data types to reveal clinically meaningful patient subgroups with enhanced interpretability.
Area of Science:
- Biomedical data science
- Computational biology
- Neuroscience
Background:
- Multimodal biomedical datasets, common in neurodegenerative diseases, pose challenges for patient stratification due to missing data, high dimensionality, and biases.
- Existing clustering methods often require extensive preprocessing and struggle to integrate heterogeneous data types effectively.
Purpose of the Study:
- To introduce ci-fGBD (Cluster-Integrated Fast Generalized Bruhat Decomposition), a novel framework for stratifying heterogeneous patient populations using multimodal data.
- To develop a method that natively handles block-structured, multimodal datasets and harmonizes contributions across diverse data types.
Main Methods:
- ci-fGBD is a matrix factorization and clustering framework extending the classical Bruhat decomposition.
- It jointly learns latent representations and patient clusters, automatically harmonizing contributions from neuroimaging, cognitive assessments, genomics, wearable sensors, and environmental exposures.
Main Results:
- Benchmarking on real-world datasets demonstrates ci-fGBD's superior performance compared to standard methods.
- The framework consistently identifies clinically meaningful subgroups in Alzheimer disease cohorts.
- ci-fGBD captures subtle biological, cognitive, and demographic heterogeneity with enhanced interpretability and robustness.
Conclusions:
- ci-fGBD offers a robust and interpretable solution for stratifying complex patient populations using multimodal biomedical data.
- The framework effectively addresses challenges posed by missing values, high dimensionality, and modality-specific biases in neurodegenerative disease research.
More Related Videos
Related Concept Videos
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Alzheimer's Disease: Treatment
825
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
825

